Device inadequacy seen as factor in failure of encapsulated cell therapy to meet goal

SAN FRANCISCO — Device inadequacy and wrong patient population were postulated as contributing factors in the failure of NT-503-3, an encapsulated cell therapy, to meet its primary goal of fewer than 20% of patients requiring rescue therapy following implant placement.“The encapsulated cell technology [Neurotech] did what it was supposed to; however, a high rate of rescue events resulted in early study termination,” Szilárd Kiss, MD, said at the American Society of Retina Specialists annual meeting.